Technical Analysis for PCRX - Pacira Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade D 40.04 3.38% 1.31
PCRX closed up 3.38 percent on Friday, January 18, 2019, on approximately normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Up
See historical PCRX trend table...

Date Alert Name Type % Chg
Jan 18 1,2,3 Retracement Bearish Bearish Swing Setup 0.00%
Jan 18 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Jan 18 Crossed Above 20 DMA Bullish 0.00%
Jan 18 Multiple of Ten Bullish Other 0.00%
Jan 18 Up 3 Days in a Row Strength 0.00%
Jan 17 MACD Bullish Signal Line Cross Bullish 3.38%
Jan 17 Inside Day Range Contraction 3.38%
Jan 15 Spinning Top Other 7.17%
Jan 15 Narrow Range Bar Range Contraction 7.17%
Jan 15 NR7 Range Contraction 7.17%

Older signals for PCRX ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, commercializes, and manufactures pharmaceutical products for use in hospitals and ambulatory surgery centers worldwide. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology. The company markets EXPAREL, a liposome injection of bupivacaine, an amide-type local anesthetic, indicated for administration into the surgical site to produce postsurgical analgesia; and DepoCyt(e), a liposomal formulation of the chemotherapeutic agent cytarabine indicated for the intrathecal treatment of lymphomatous meningitis, a cancer of the immune system. Its product pipeline comprise EXPAREL that has completed Phase II clinical trials for postsurgical analgesia-nerve block administration; DepoNSAID, which is in preclinical trials for the relief of acute pain; and DepoMethotrexate that is in preclinical trials for the treatment of rheumatoid arthritis and oncology, as well as Bupivacaine Liposome Injectable Suspension for veterinary postsurgical analgesia. Pacira Pharmaceuticals, Inc. has a development and commercialization agreement, and related supply agreement with Aratana Therapeutics, Inc. The company was formerly known as Pacira, Inc. and changed its name to Pacira Pharmaceuticals, Inc. in October 2010. Pacira Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Parsippany, New Jersey.
Is PCRX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 55.0
52 Week Low 26.95
Average Volume 523,922
200-Day Moving Average 41.4543
50-Day Moving Average 44.3862
20-Day Moving Average 39.9205
10-Day Moving Average 38.413
Average True Range 2.0619
ADX 33.39
+DI 16.0473
-DI 22.2146
Chandelier Exit (Long, 3 ATRs ) 39.8143
Chandelier Exit (Short, 3 ATRs ) 41.7657
Upper Bollinger Band 44.1057
Lower Bollinger Band 35.7353
Percent B (%b) 0.51
BandWidth 20.967673
MACD Line -1.7404
MACD Signal Line -1.9691
MACD Histogram 0.2287
Fundamentals Value
Market Cap 1.62 Billion
Num Shares 40.4 Million
EPS -1.72
Price-to-Earnings (P/E) Ratio -23.28
Price-to-Sales 4.67
Price-to-Book 5.03
PEG Ratio -3.43
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 42.61
Resistance 3 (R3) 42.41 41.37 42.18
Resistance 2 (R2) 41.37 40.71 41.46 42.03
Resistance 1 (R1) 40.70 40.31 41.04 40.90 41.89
Pivot Point 39.66 39.66 39.82 39.75 39.66
Support 1 (S1) 38.99 39.00 39.33 39.19 38.19
Support 2 (S2) 37.95 38.60 38.04 38.05
Support 3 (S3) 37.28 37.95 37.90
Support 4 (S4) 37.48